Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
SAN DIEGO, Sept. 26 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that it has been selected to be one of the
inaugural companies in the new NASDAQ® NeuroInsights® Neurotech Index.
The NASDAQ NeuroInsights Neurotech Index is an index designed to track the
performance of selected neurotechnology companies which are listed on one of
the three major U.S. stock exchanges. The NASDAQ NeuroInsights Neurotech Index
includes companies engaged in researching, developing, manufacturing and
marketing pharmaceuticals, biologics, medical devices and diagnostics for the
brain and nervous system. In addition to meeting minimum market criteria, the
32 companies included in the index must be identified by NeuroInsights as
significantly involved in the neurotechnology industry, which includes
treatments and diagnostics for disorders like Alzheimer's, addiction, anxiety,
depression, epilepsy, multiple sclerosis, obesity, pain, Parkinson's,
schizophrenia, sensory disorders, sleep disorders, stroke, and traumatic brain
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing oral drugs in four major
therapeutic areas: cardiovascular, central nervous system, inflammatory, and
metabolic diseases. Arena's most advanced product candidate, lorcaserin, is
being investigated in a Phase 3 clinical trial program for the treatment of
obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled
receptors, an important class of validated drug targets, includes compounds
being evaluated independently and with its partners, Merck & Co., Inc. and
Ortho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals® and Arena® are registered service marks of the
company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, preclinical and internal
and partnered clinical programs, and ability to develop compounds and
commercialize drugs. For such statements, Arena claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or results may
differ materially from Arena's expectations. Factors that could cause actual
results to differ materially from the forward-looking statements include, but
are not limited to, Arena's planned clinical trials may not proceed at the
time Arena expects or at all, the results of preclinical studies or clinical
trials may not be predictive of future results, Arena's ability to partner
lorcaserin, APD125, APD791 or other of its compounds or programs, the timing,
success and cost of Arena's research, out-licensing endeavors and clinical
trials, Arena's ability to obtain additional financing, Arena's ability to
obtain and defend its patents, and the timing and receipt of payments and
fees, if any, from Arena's collaborators. Additional factors that could cause
actual results to differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking statements represent
Arena's judgment as of the time of this release. Arena disclaims any intent or
obligation to update these forward-looking statements, other than as may be
required under applicable law.
SOURCE Arena Pharmaceuticals, Inc.
CONTACT: Jack Lief, President and CEO, or David Walsey, Director,
Corporate Communications, both of Arena Pharmaceuticals, Inc., +1-858-453-
7200, ext. 1682; or Mary Claire Duch of WeissComm Partners, +1-212-301-7228,
for Arena Pharmaceuticals, Inc.
Web site: http://www.arenapharm.com